Eliglustat hemitartrate

CAS No. 928659-70-5

Eliglustat hemitartrate ( Genz-112638,Eliglustat tartrate )

Catalog No. M22931 CAS No. 928659-70-5

Eliglustat Hemitartrate, with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Eliglustat tartrate shows good potency with an IC50 of 24 nM and specificity against the target enzyme.A novel inhibitor of glucosylceramide synthase (Genz-112638) and assessed its activity in a murine model of Gaucher disease (D409V/null).?Biochemical characterization of Genz-112638 showed good potency (IC(50) approximately 24nM) and specificity against the target enzyme.?

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 86 In Stock
10MG 116 In Stock
25MG 176 In Stock
50MG 233 In Stock
100MG 431 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Eliglustat hemitartrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Eliglustat Hemitartrate, with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Eliglustat tartrate shows good potency with an IC50 of 24 nM and specificity against the target enzyme.A novel inhibitor of glucosylceramide synthase (Genz-112638) and assessed its activity in a murine model of Gaucher disease (D409V/null).?Biochemical characterization of Genz-112638 showed good potency (IC(50) approximately 24nM) and specificity against the target enzyme.?
  • Description
    Eliglustat Hemitartrate, with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor.Eliglustat tartrate shows good potency with an IC50 of 24 nM and specificity against the target enzyme.A novel inhibitor of glucosylceramide synthase (Genz-112638) and assessed its activity in a murine model of Gaucher disease (D409V/null).?Biochemical characterization of Genz-112638 showed good potency (IC(50) approximately 24nM) and specificity against the target enzyme.?Mice that received drug prior to significant accumulation of substrate (10 weeks of age) showed reduced levels of glucosylceramide and number of Gaucher cells in the spleen, lung and liver when compared to age-matched control animals.?Treatment of older mice that already displayed significant amounts of tissue glucosylceramide (7 months old) resulted in arrest of further accumulation of the substrate and appearance of additional Gaucher cells in affected organs.?These data indicate that substrate inhibition therapy with Genz-112638 represents a viable alternate approach to enzyme therapy to treat the visceral pathology in Gaucher disease.
  • Synonyms
    Genz-112638,Eliglustat tartrate
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    glucocerebroside synthase
  • Research Area
    Metabolism
  • Indication
    Gaucher′s Disease

Chemical Information

  • CAS Number
    928659-70-5
  • Formula Weight
    959.17
  • Molecular Formula
    C50H78N4O14
  • Purity
    >98% (HPLC)
  • Solubility
    H2O:50 mg/mL (52.13 mM);DMSO:50 mg/mL (52.13 mM)
  • SMILES
    CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](C2=CC=C(OCCO3)C3=C2)O)=O.CCCCCCCC(N[C@H](CN4CCCC4)[C@@H](C5=CC=C(OCCO6)C6=C5)O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. McEachern KA, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy ofGaucher disease. Mol Genet Metab. 2007 Jul;91(3):259-67.
molnova catalog
related products
  • 2,4-Dihydroxy-6-meth...

    2,4-Dihydroxy-6-methoxyacetophenone exhibits a moderate antispasmodic activity.

  • m-PEG8-O-alkyne

    m-PEG8-O-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

  • STK16-IN-1

    STK16-IN-1 is an inhibitor of STK16 kinase (IC50: 295 nM).